Cost-Effectiveness of Preventing Loss to Follow-up in HIV Treatment Programs: A Cote d'Ivoire Appraisal

被引:59
作者
Losina, Elena [1 ,2 ,3 ]
Toure, Hapsatou [4 ]
Uhler, Lauren M. [1 ]
Anglaret, Xavier [4 ,5 ]
Paltiel, A. David [6 ]
Balestre, Eric [4 ]
Walensky, Rochelle P. [1 ,7 ,8 ,9 ,10 ]
Messou, Eugene [5 ]
Weinstein, Milton C. [7 ]
Dabis, Francois [4 ]
Freedberg, Kenneth A. [1 ,7 ,8 ,9 ,10 ,11 ]
机构
[1] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA
[2] Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA
[3] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA
[4] Univ Victor Segalen, ISPED, INSERM, U897, Bordeaux, France
[5] Ctr Prise Charge Rech & Format, Abidjan, Cote Ivoire
[6] Yale Univ, New Haven, CT USA
[7] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA
[8] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA
[9] Harvard Univ, Sch Med, Ctr AIDS Res, Boston, MA USA
[10] Harvard Univ, Sch Med, Dept Med, Boston, MA USA
[11] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA
基金
美国国家卫生研究院;
关键词
ANTIRETROVIRAL THERAPY PROGRAMS; RESOURCE-POOR SETTINGS; RAPID SCALE-UP; INFECTED ADULTS; TREATMENT SERVICE; CLINICAL IMPACT; LOW-INCOME; MORTALITY; COHORT; SURVIVAL;
D O I
10.1371/journal.pmed.1000173
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Data from HIV treatment programs in resource-limited settings show extensive rates of loss to follow-up (LTFU) ranging from 5% to 40% within 6 mo of antiretroviral therapy (ART) initiation. Our objective was to project the clinical impact and cost-effectiveness of interventions to prevent LTFU from HIV care in West Africa. Methods and Findings: We used the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) International model to project the clinical benefits and cost-effectiveness of LTFU-prevention programs from a payer perspective. These programs include components such as eliminating ART co-payments, eliminating charges to patients for opportunistic infection-related drugs, improving personnel training, and providing meals and reimbursing for transportation for participants. The efficacies and costs of these interventions were extensively varied in sensitivity analyses. We used World Health Organization criteria of <3x gross domestic product per capita (3x GDP per capita = US$2,823 for Cote d'Ivoire) as a plausible threshold for "cost-effectiveness." The main results are based on a reported 18% 1-y LTFU rate. With full retention in care, projected per-person discounted life expectancy starting from age 37 y was 144.7 mo (12.1 y). Survival losses from LTFU within 1 y of ART initiation ranged from 73.9 to 80.7 mo. The intervention costing US$22/person/year (e. g., eliminating ART co-payment) would be cost-effective with an efficacy of at least 12%. An intervention costing US$77/person/year (inclusive of all the components described above) would be cost-effective with an efficacy of at least 41%. Conclusions: Interventions that prevent LTFU in resource-limited settings would substantially improve survival and would be cost-effective by international criteria with efficacy of at least 12%-41%, depending on the cost of intervention, based on a reported 18% cumulative incidence of LTFU at 1 y after ART initiation. The commitment to start ART and treat HIV in these settings should include interventions to prevent LTFU.
引用
收藏
页数:11
相关论文
共 65 条
[1]   Lessons learned from use of highly active antiretroviral therapy in Africa [J].
Akileswaran, C ;
Lurie, MN ;
Flanigan, TP ;
Mayer, KH .
CLINICAL INFECTIOUS DISEASES, 2005, 41 (03) :376-385
[2]   Impact of vital status investigation procedures on estimates of survival in cohorts of HIV-infected patients from sub-Saharan Africa [J].
Anglaret, X ;
Toure, S ;
Gourvellec, G ;
Tchehy, A ;
Zio, L ;
Zaho, M ;
Kassi, MC ;
Lehou, J ;
Coulibaly, H ;
Seyler, C ;
N'Dri-Yoman, T ;
Salamon, R ;
Chêne, G .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 35 (03) :320-323
[3]  
[Anonymous], 1996, Cost-effectiveness in health and medicine
[4]  
[Anonymous], CURRENT HIV AIDS REP
[5]  
[Anonymous], AIDS EP UPD DEC 2007
[6]  
[Anonymous], UN ACC SCAL PRIOR HI
[7]  
[Anonymous], 2001, MACROECONOMICS HLTH
[8]  
[Anonymous], 2006, ANT THER HIV INF AD
[9]  
BEAULIERE A, 2008, 15 INT C AIDS STIS A
[10]  
Bekker LG, 2006, SAMJ S AFR MED J, V96, P315